Be part of the knowledge.™

Novel Therapies for HDL Cholesterol

Media Formats

ReachMD Healthcare Image

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details

Presenters

Overview
Will novel HDL cholesterol therapies reduce cardiovascular risk? Dr. Robert Rosenson will discuss the hope for CETP inhibitors and HDL mimetics to modify HDL cholesterol and coronary heart disease risk.

Robert S. Rosenson, MD

Robert S. Rosenson, MD

Matthew J. Sorrentino, MD, FACC, FASH

Matthew J. Sorrentino, MD, FACC, FASH

Recommended

Details

Presenters

Overview
Will novel HDL cholesterol therapies reduce cardiovascular risk? Dr. Robert Rosenson will discuss the hope for CETP inhibitors and HDL mimetics to modify HDL cholesterol and coronary heart disease risk.

Robert S. Rosenson, MD

Robert S. Rosenson, MD

Matthew J. Sorrentino, MD, FACC, FASH

Matthew J. Sorrentino, MD, FACC, FASH

Program Chapters

Segment Chapters

Playlist:

Recommended

FCS and SHTG: Are We Meeting the Need?

Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future

Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective

$IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement$

IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement

Level Up Your Skills: Tailoring Management of HF

Navigating Myasthenia Gravis in Adolescents and Young Adults

Clinician's Roundtable

Challenges in AI-Driven Dermatology: Understanding Current Limitations

Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial